Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Mirum Pharmaceuticals, Inc. reported revenue of $521M, up 54.7% year over year. Operating margin was -4.2% and net margin -4.5%, on a free-cash-flow margin of 10.5% with capital expenditure at 0.2% of revenue. Every figure is computed directly from MIRM's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $521M | -4.2% | -4.5% |
| FY2024 | $337M | -26.0% | -26.1% |
| FY2023 | $186M | -58.6% | -87.7% |
| FY2022 | $77M | -170.3% | -176.0% |
| FY2021 | $19M | -906.1% | -438.9% |
How does MIRM compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.